Clinicians who encounter refractory or episodic hypertension in patients with known or suspected NSCLC should obtain plasma metanephrines and chromogranin A levels early, begin alpha-adrenergic blockade before any beta-blocker, and expedite oncologic staging to guide tumor-directed therapy. Here, CHGA is linked to neoplasm.